CTOs on the Move

Principia Biopharma

www.principiabio.com

 
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.principiabio.com
  • 400 E Jamie Ct Suite 302
    South San Francisco, CA USA 94080
  • Phone: 650.416.7700

Executives

Name Title Contact Details

Funding

Principia Biopharma raised $15.3M on 08/10/2015

Similar Companies

DxTech

DxTech LLC is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CureVac

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing this versatile biological molecule for medical purposes. The principle of CureVac`s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac`s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA.

OMICS Group Inc

OMICS Group Inc is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProZyme

ProZyme is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amisure International

Amisure International is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.